Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses persistent sexual and nonsexual adverse effects of the 5α-reductase inhibitor finasteride in younger men, including erectile dysfunction, low libido, and depression. It reports no new clinical results but emphasizes further research is needed.

This study found that 94% of healthy men reported low libido and 92% reported erectile dysfunction as persistent sexual side effects after using finasteride for male pattern hair loss, with these effects lasting on average 40 months post-discontinuation.

Finasteride, a hair loss drug, can cause long-lasting sexual side effects like low libido and erectile dysfunction.

Testosterone replacement can help menopausal women with various symptoms, but should be used carefully and is not yet officially licensed in the UK for women.

Many women experience sexual dysfunction, but few seek help, and better treatment and medical training are needed.

This review discusses sexual side effects in men with androgenic alopecia treated with 5-alpha reductase inhibitors and reports no new clinical findings.

This article examines 5 alpha-reductase inhibitors and their link to persistent sexual dysfunction, but it reports no new clinical findings.

This review discusses adverse effects of 5 alpha-reductase inhibitors, particularly persistent side effects such as post-finasteride syndrome, and highlights the need for further investigation.

This article discusses the sexual health issues faced by postmenopausal women and highlights the need for more research and tailored treatments, but it reports no new clinical results.

This review discusses the adverse effects of 5α-reductase inhibitors, finasteride and dutasteride, on sexual, psychological, and vascular health, emphasizing the need for physicians to inform patients of these risks.

This review discusses post-finasteride syndrome, highlighting occasional adverse sexual and systemic effects in men and women, but reports no new research findings while emphasizing the need for better education about the drug's risks.

This study developed two highly reliable Arabic HRQoL questionnaires for evaluating quality of life in married and unmarried women with polycystic ovary syndrome.

This review discusses the neurobiology of sexual function and reports no new results; the authors cover multiple endocrine and neurotransmitter influences on sexual desire, arousal, and orgasm stages.

This document by the AACE and AES provides a 2015 summary of best practices for diagnosing and managing PCOS, emphasizing clinical assessment and treatment options but reports no new clinical results.

This review provides updated guidelines for diagnosing and managing women's sexual dysfunctions but reports no new clinical findings; it emphasizes the need for ongoing research and long-term outcome studies.

This study observed enduring sexual dysfunction reported in 300 cases globally following the use of SSRIs, finasteride, and isotretinoin, with common symptoms like genital anaesthesia and loss of libido.

This review examines various androgen deprivation therapy methods for advanced prostate cancer, highlighting benefits and potential cardiovascular and sexual adverse effects, but reports no new clinical results.

This review discusses post-SSRI sexual dysfunction syndrome and highlights its significant clinical and regulatory implications, but reports no new findings.

This study found that women with nonclassic congenital adrenal hyperplasia (NC-CAH) reported lower sexual function and higher sexual distress compared to those with classic CAH (C-CAH), particularly among those showing signs of androgen excess.

This review discusses the psychiatric and sexual comorbidities of PCOS, emphasizing the need for a multidisciplinary approach to manage sexual dysfunction due to high prevalence rates found in recent studies.

This review examines medical literature on postfinasteride syndrome and reports no new results; the authors call for more controlled studies on permanent sexual dysfunction and mood changes linked to 5-alpha-reductase inhibitors.

Older adults still engage in sexual activities but face challenges like health issues and lack of professional support, highlighting the need for better healthcare provider education and research on sexual fulfillment in old age.

This review discusses the roles of hormonal pathways in regulating male sexual function, particularly highlighting the impact of testosterone, and reports no new research findings.

This article discusses the FDA approval of bremelanotide for premenopausal women with hypoactive sexual desire disorder and reports no clinical results.

This review discusses management strategies for sexual side effects of aromatase inhibitors in postmenopausal breast cancer patients and reports no original clinical findings.

This review discusses the impact of hormones on female sexual function and dysfunction, highlighting the complexity and gaps in basic research, and reports no new clinical findings.

Testosterone therapy can improve sexual function in women but long-term safety is unclear.

Menopause often leads to lower sexual desire and discomfort during sex, but treatment should be personalized and only if it bothers the woman.

This review discusses the challenges in addressing female sexual dysfunction, focusing on the complexities of female sexual response, levels of dysfunction, clinical identification, and existing treatments, but presents no new clinical findings.

This study found that dutasteride use is associated with increased reports of sexual dysfunction, based on data from the U.S. Food and Drug Administration Adverse Event Reporting System.